ライフサイエンスコーパス: pseudotyped

1 All pseudotyped AAV vectors elicited serum anti-AAV capsid-n

2 ingle and repeat administrations of multiple pseudotyped adeno-associated virus (AAV) vectors as a me

3 s linked to a GFP reporter and packaged in a pseudotyped adenoassociated viral vector (AAV2/5).

4 d entry kinetics of native viruses and their pseudotyped analogs.

5 ng antibodies against infection by divergent pseudotyped and live MERS-CoV strains, as well as antibo

6 highest-affinity MAb, m336, neutralized both pseudotyped and live MERS-CoV with exceptional potency,

7 The fiber-pseudotyped and penton base constructs with RGD deleted

8 hibited IC(50) values of less than 5 nM in a pseudotyped antiviral assay, and compound 13k was demons

9 ntiviral potency comparable to 26 in the M33 pseudotyped antiviral assay.

10 on glass slides 'printed' with lentiviruses pseudotyped as vesicular stomatitis virus glycoprotein,

11 HIV vectors pseudotyped by WEEV GP may be a useful tool for characte

12 r in the mouse nose with A. californica GP64-pseudotyped FIV (AcGP64-FIV).

13 ese findings demonstrate the utility of GP64-pseudotyped FIV lentiviral vectors for targeting hepatoc

14 We generated a GP64-pseudotyped FIV vector encoding the B domain-deleted hum

15 ind broad use given the extensive tropism of pseudotyped FIV vectors for many cell types in vitro and

16 ated vesicular stomatitis virus glycoprotein-pseudotyped FIV.

17 erapy by use of a gibbon-ape-leukaemia-virus pseudotyped gammaretroviral vector.

18 fection mediated by the HeV glycoproteins in pseudotyped-HeV entry assays more effectively than the c

19 s and enhanced the cell entry of both SARS S-pseudotyped HIV and authentic SARS-CoV.

20 ect on human immunodeficiency virus (HIV) GP pseudotyped HIV or adeno-associated virus 2 vector entry

21 Using Ebola Zaire GP-pseudotyped HIV particles bearing a luciferase reporter

22 induced an antiviral state in astrocytes, a pseudotyped HIV viral particle, vesicular stomatitis vir

23 rameshift efficiency, and infectivity, using pseudotyped HIV-1 and HEK293T cells.

24 to CCR5-tropic HIV-1 infection but not VSV G-pseudotyped HIV-1 infection.

25 Finally, we employed a cell-based pseudotyped HIV-1 mutation assay to determine whether ch

26 HIV-1 or murine leukemia virus Env (MLV-Env)-pseudotyped HIV-1 particles was enhanced in IFN-alpha-tr

27 or expression, as vesicular stomatitis virus-pseudotyped HIV-1 replication was also blocked by IL-12/

28 pan-neutralization against a panel of 56 Env-pseudotyped HIV-1 representing diverse subtypes of clini

29 d not lead to increased infection with VSV-G-pseudotyped HIV-1 vectors.

30 and they strongly inhibit the infectivity of pseudotyped HIV-1 virions.

31 ansfection production of a Sendai virus F/HN-pseudotyped HIV-1-based third generation lentiviral vect

32 potent than 4E10 against several isolates of pseudotyped HIV-1.

33 ular stomatitis virus G glycoprotein (VSV-G)-pseudotyped HIV-1.

34 na) long-term repopulating cells using VSV-G-pseudotyped HIV-based lentiviral vectors.

35 had greater susceptibility to infection with pseudotyped HIV.

36 nfirmed that Tat expression and infection of pseudotyped HIV.GFP led to increased lysosomal exocytosi

37 The titers of WEEV GP-pseudotyped human immunodeficiency virus type 1 (HIV) ra

38 iral activity of these compounds in an Ebola pseudotyped infection model was in the low micromolar ra

39 We have produced a pseudotyped influenza virus based on suppression of the

40 rescue HIV-1 or vesicular stomatitis virus G-pseudotyped lentivectors infection in LC.

41 ular stomatitis virus glycoprotein G (VSV-G)-pseudotyped lentiviral gene therapy vector could also in

42 ly impaired entry of genotype 1a HCV and HCV-pseudotyped lentiviral particles (HCVpp) in Huh-7 cells

43 ed with vesicular stomatitis virus-G (VSV-G)-pseudotyped lentiviral vector but not with vector pseudo

44 e of melanoma cells and targeted by the m168 pseudotyped lentiviral vector conjugated with antibody s

45 We found that the VSV-G-pseudotyped lentiviral vector failed to fuse to resting

46 ified gibbon ape leukemia virus glycoprotein-pseudotyped lentiviral vector infectivity of HSPCs, the

47 ped a novel targeting Sindbis virus envelope pseudotyped lentiviral vector, 2.2ZZ, which acquires spe

48 When pseudotyped lentiviral vectors encoding green fluorescen

49 fuse to resting CD4(+) T cells while HIV Env-pseudotyped lentiviral vectors fused, reverse transcribe

50 Rabies pseudotyped lentiviral vectors have great potential in g

51 as the major entry port of VSV and of VSV-G-pseudotyped lentiviral vectors in human and mouse cells,

52 sed to the cytoplasmic tail (CT) of gp41 and pseudotyped lentiviral vectors with them.

53 Using pseudotyped lentiviral vectors, we found that a soluble

54 fficient delivery to primitive HPCs by VSV-G-pseudotyped lentiviral vectors.

55 ral receptor TVB (TVB-NRG1), along with EnvB pseudotyped lentivirus (LV) and rabies virus (RV), to se

56 dy, the VSV-G (vesicular stomatitis virus G) pseudotyped lentivirus is not and allows us to control f

57 re transduced with HLA-A2.1-expressing VSV-G-pseudotyped lentivirus or retrovirus vectors under ident

58 ransfer of Nipah virus envelope glycoprotein-pseudotyped lentivirus particles by MDCs were severely a

59 Neonatal intravascular injection of VSV-G pseudotyped lentivirus resulted in almost exclusive tran

60 potently reduced gene transfer of HIV-1 Env-pseudotyped lentivirus vectors and inhibited the replica

61 ransduction rates with VSV-G-, RRV-, and SFV-pseudotyped lentivirus vectors into adherent cell lines

62 h are predominantly quiescent, by generating pseudotyped-lentivirus.

63 eutralizing variant hemagglutinin-expressing pseudotyped lentiviruses.

64 Vesicular stomatitis virus G protein (VSV-G)-pseudotyped LV preparations produced by transient transf

65 of TVS markedly reduces the ability of VSV-G-pseudotyped LV preparations to activate pDC.

66 Pseudotyped LV vectors containing glia-specific promoter

67 attained with subretinal injection of VSV-G pseudotyped LV vectors containing the CD44 promoter.

68 tion by vesicular stomatitis virus G protein pseudotyped M-PMV.

69 These findings indicate the utility of VSVG-pseudotyped MLV for transgenesis of S. mansoni, herald a

70 Using CERV2 Env-pseudotyped MLV reporters, we identified copper transpor

71 chistosomula were exposed to virions of VSVG-pseudotyped MLV, after which genomic DNA was extracted f

72 (ancHTenv) that could support infection of a pseudotyped modern gammaretrovirus.

73 When pseudotyped on HIV-1 virions, the A-MLV and ASLV-A Envs

74 ed two MAbs that can strongly neutralize HCV-pseudotyped particles (HCVpp) bearing the envelope glyco

75 lycoprotein sequences were tested in the HCV pseudotyped particles (HCVpp) system.

76 ing cells much more efficiently than did HeV pseudotyped particles (HeVpp), and (iii) NiVpp but not H

77 gth NiV-G, resulted in optimal titers of NiV-pseudotyped particles (NiVpp) ( approximately 10(6) IU/m

78 The host range of the pseudotyped particles in vitro was somewhat limited, whi

79 Vesicular stomatitis virus G protein-pseudotyped particles were prepared from a library of >1

80 HIV-1 efficiently forms pseudotyped particles with many gammaretrovirus glycopro

81 ne leukemia virus (MLV) Env can readily form pseudotyped particles with many retroviruses, suggesting

82 pe 1 (HIV-1) in the production of infectious pseudotyped particles.

83 infected with Ebola virus glycoprotein (GP)-pseudotyped particles.

84 ed susceptibility to both HTLV-1- and HTLV-2-pseudotyped particles.

85 viruses to form infectious virions known as pseudotyped particles.

86 Pseudotyped rAAV transduced islet grafts maintained norm

87 Pseudotyped rAAV2/1 based vectors transduced murine isle

88 We used a pseudotyped rAAV2/5 vector to express human wild-type (w

89 We tested pseudotyped rAAVs of several common serotypes (rAAV 2/1,

90 Using pseudotyped rabies virus in a transgenic Gpr151-Cre mous

91 rons were susceptible to infection with EnvA-pseudotyped rabies virus in tumor virus A receptor trans

92 R and generated vesicular stomatitis virus-G-pseudotyped recombinant retrovirus by transfection into

93 oped vesicular stomatitis virus glycoprotein-pseudotyped replication-defective simian immunodeficienc

94 We report that pseudotyped, replication-incompetent retroviruses can be

95 inity than that of sHeV-G, (ii) NiV envelope pseudotyped reporter virus (NiVpp) entered ephrinB3-expr

96 35 untreated HIV-2-infected subjects using a pseudotyped reporter virus assay.

97 seudotyped viral entry assay, where receptor-pseudotyped reporter virus was used to infect cells expr

98 hepatocytes was examined directly using HCV-pseudotyped retroviral particles (HCV-pp).

99 However, pseudotyped retroviral particles (pp) bearing the HCV en

100 n of human HSCs with either FeLV-C- or RD114-pseudotyped retroviral particles may improve gene transf

101 od, expanded in culture, and transduced with pseudotyped retroviral vectors expressing human eNOS (eN

102 nvelopes between PERV-A and PERV-C and using pseudotyped retroviral vectors to map the human cell tro

103 ACE2 potently blocked infection by S-protein-pseudotyped retrovirus and by SARS-CoV.

104 Rabbit anti-GBV-C E2 Abs neutralized HIV-1-pseudotyped retrovirus particles but not HIV-1-pseudotyp

105 e binding of soluble CD81 to immobilized HCV-pseudotyped retrovirus particles.

106 cDNA library in vesicular stomatitis virus G pseudotyped retrovirus was transduced into Chinese hamst

107 numbers of FeLV-C and GALV or RD114 and GALV-pseudotyped retroviruses for injection into fetal sheep.

108 g but that OCEV glycoprotein precursor (GPC)-pseudotyped retroviruses poorly entered 53 human cancer

109 y resistant to infection by flaviviruses and pseudotyped retroviruses, but infection can be restored

110 or the M2 proton pump, inhibits entry of HA-pseudotyped retroviruses.

111 or inhibited GP(1,2)-mediated cell entry of pseudotyped retroviruses.

112 We generated high titers of GP-pseudotyped rLCMVDeltaGP/GFP via genetic trans complemen

113 Replication of these GP-pseudotyped rLCMVDeltaGP/GFP viruses was restricted to G

114 Using GP-pseudotyped rLCMVDeltaGP/GFP, we have also obtained evid

115 Furthermore, AAV5-pseudotyped scAAV vectors mediated successful transducti

116 l vein administration of 1x10(12) vg/kg AAV5-pseudotyped scAAV-LP1-hFIXco.

117 We infused a single dose of a serotype-8-pseudotyped, self-complementary adenovirus-associated vi

118 d that the transduction of DCs in vitro with pseudotyped single-cycle SIVs expressing IFN-gamma incre

119 The data support F/HN-pseudotyped SIV as a promising vector for pulmonary gene

120 posure to a low concentration of amphotropic pseudotyped SIV vector particles encoding the green fluo

121 Using S-protein-pseudotyped SIV, we found that the enzymatic activity of

122 not alter the infectivity or antigenicity of pseudotyped SIV.

123 eviously showed that IFN-gamma expression by pseudotyped SIVs does not alter viral single-cycle infec

124 ls primed with dendritic cells transduced by pseudotyped SIVs expressing high levels of IFN-gamma had

125 udy, we tested the immunogenicities of these pseudotyped SIVs in a rat model.

126 roblasts with a vesicular stomatitis virus G-pseudotyped strain of HIV-1 produced similar results, su

127 In contrast, the infectivity of HIV virions pseudotyped to enter cells via endocytosis, which is kno

128 across residues 660 to 680 in the MPER of a pseudotyped variant of HIV-1(JR-FL), designated HIV-1(JR

129 ins in feline cells restricts FIV, impairing pseudotyped vector transduction and viral replication, b

130 ion significantly increased EBOV GP and VSVG pseudotyped vector transduction but had minimal effect o

131 The GP64-pseudotyped vector was stable in the presence of human o

132 tion of vesicular stomatitis virus GP (VSVG) pseudotyped vector.

133 Our data emphasize both the utility of GP-pseudotyped vectors in the assessment of compounds that

134 RV-G pseudotyped vectors were co-transported with both the te

135 ent sheep demonstrated that FeLV-C- or RD114-pseudotyped vectors were present at significantly higher

136 Unlike vesicular stomatitis virus G protein-pseudotyped vectors, they are not neutralized by complem

137 infectivity or tropism from wild-type VSV-G-pseudotyped vectors.

138 ent at significantly higher levels than GALV-pseudotyped vectors.

139 genomes were packaged within F-MuLV virions (pseudotyped) very soon after infection.

140 subsequently show the specific detection of pseudotyped vesicular stomatitis virus (VSV) as a model

141 In this work, we developed a pseudotyped vesicular stomatitis virus (VSV) with a glyc

142 eudotyped retrovirus particles but not HIV-1-pseudotyped vesicular stomatitis virus particles, and E2

143 ermore, expression of HAP2 on the surface of pseudotyped vesicular stomatitis virus results in homoty

144 h wild-type PPRV were able to neutralize RPV-pseudotyped vesicular stomatitis virus.

145 These results were corroborated in a reverse-pseudotyped viral entry assay, where receptor-pseudotype

146 on of HTLV-1 virions and the titer of HTLV-1 pseudotyped viral infection in CD4(+) T cells.

147 coexpressed with GhV-G protein, and mediates pseudotyped viral particle entry.

148 as a mechanism of uptake of EBOV GP and VSVG pseudotyped viral particles.

149 dly reduced binding avidity compared to FB29-pseudotyped viral particles.

150 property, recombinant forms of VSV and VSV-G-pseudotyped viral vectors are being developed for gene t

151 VSV and for the broad applicability of VSV-G-pseudotyped viral vectors for gene transduction.

152 SARS-CoV S, followed by cell-cell fusion and pseudotyped virion infectivity assays, showed a critical

153 ify inhibitors of arenavirus infection using pseudotyped virion particles bearing the glycoproteins (

154 Moreover, pseudotyped virions carrying these N-glycan mutants had

155 , inhibited SARS-CoV S-mediated entry of the pseudotyped virions in 293T cells expressing a functiona

156 Entry of pseudotyped virions required a gD receptor and was inhib

157 that membrane fusion during the entry of the pseudotyped virions shares common requirements with the

158 idate genes were identified by using EBOV GP pseudotyped virions to transduce human tumor cell lines

159 Infection of cells by these pseudotyped virions was blocked by lysosomotropic agents

160 try for Ebola virus (EBOV) glycoprotein (GP) pseudotyped virions, we used comparative gene analysis t

161 can affect VCA analyses, particularly using pseudotyped virions.

162 ells or against vesicular stomatitis virus-G pseudotyped virions.

163 urine leukemia virus Env cytoplasmic tail in pseudotyped virions.

164 ere infected with HIV-1/vesicular stomatitis-pseudotyped virus and stereotactically injected into the

165 ve used a human immunodeficiency virus-based pseudotyped virus as a surrogate system to dissect the r

166 We show that VSV-G-pseudotyped virus cannot fuse to unstimulated cells beca

167 epithelia facilitated SARS spike (S) protein-pseudotyped virus entry.

168 were screened for neutralization of an SF162-pseudotyped virus in a luciferase assay.

169 susceptible to both EboV RBD binding and GP-pseudotyped virus infection than their nonadherent count

170 chloroquine, as highly active inhibitors of pseudotyped virus infection.

171 ormation, despite effectively inhibiting the pseudotyped virus infection.

172 nd C HIV-1 strains, synergistically in a Env-pseudotyped virus neutralization assay.

173 e of the FAbs neutralized the infectivity of pseudotyped virus particles (pp) bearing the envelope gl

174 eover, these cells specifically bound FeLV-A-pseudotyped virus particles, indicating that the cDNA en

175 d single round vescicular stomatitis virus-G pseudotyped virus replication, whereas superinfection of

176 the SF162 virus with the JR-FL V3 created a pseudotyped virus that was hypersensitive to neutralizat

177 uses a lentivirus/vesicular stomatitis virus pseudotyped virus to engineer CD3/CD28-stimulated human

178 R followed by cloning of env genes to create pseudotyped virus to explore the link between genotypic

179 l receptor TVB fused to NRG, along with EnvB-pseudotyped virus, is able to direct infection selective

180 y isolates of subtypes A, B, and C in an Env-pseudotyped-virus neutralization assay, albeit with redu

181 tically and geographically diverse HIV-1 Env-pseudotyped viruses and chronic infection plasma samples

182 tent neutralization against EBOV and SUDV GP pseudotyped viruses as well as authentic pathogens, and

183 l of reference Env clones from among 219 Env-pseudotyped viruses assayed in TZM-bl cells with sera fr

184 Pseudotyped viruses bearing chimeric envelopes with earl

185 the infection by EBOV and EBOV glycoprotein pseudotyped viruses but not by the pseudotypes bearing t

186 ing using human immunodeficiency virus-based pseudotyped viruses expressing EBOV-GP.

187 ependent entry of trypsin-treated retrovirus pseudotyped viruses expressing JMD mutant S Delta19 prot

188 00 well-characterized clade C envelope (Env)-pseudotyped viruses from early infection.

189 clones were screened for infectivity as Env-pseudotyped viruses in a luciferase reporter gene assay

190 When tested as Env-pseudotyped viruses in a luciferase reporter gene assay,

191 he small molecule inhibited the entry of all pseudotyped viruses in vitro and the cleavage of SARS-Co

192 g of soluble HTLV-1 SU and the entry of HTLV pseudotyped viruses into non-T cells.

193 9 was active against 636 different HIV-1 Env-pseudotyped viruses of varying tropism and derived from

194 Assays using pseudotyped viruses suggested that these new gp120 mutat

195 tibody, 10E8V2.0/iMab, neutralized 118 HIV-1 pseudotyped viruses tested with a mean 50% inhibitory co

196 Studies of entry performed with HTLV-3 Env-pseudotyped viruses together with SU binding studies rev

197 an immunodeficiency virus type 1 (HIV-1) Env-pseudotyped viruses was created by cloning, sequencing,

198 icular stomatitis virus glycoprotein (VSV-G)-pseudotyped viruses were generated by cotransfecting 293

199 interaction, we found that Bori-15 envelope-pseudotyped viruses were significantly less sensitive th

200 from 200 southern African, clade C envelope-pseudotyped viruses with neutralization titers against 1

201 Pseudotyped viruses with V1-V2 segments from different t

202 mes and subsequently replicate and spread as pseudotyped viruses.

203 face severely impairs the infectivity of Env-pseudotyped viruses.

204 gle-cycle assay against a large panel of Env-pseudotyped viruses.

205 induce and stabilize with soluble CD4 on Env-pseudotyped viruses.

206 lope backbone and then used them to generate pseudotyped viruses.

207 reased the titer of both HTLV-I- and HTLV-II-pseudotyped viruses.

208 arge, multi-subtype panel of 30 tier 2-3 Env-pseudotyped viruses.

209 pic and vesicular stomatitis virus G (VSV-G)-pseudotyped viruses.

210 icles (VLPs) as well as infectivity of GP1,2-pseudotyped viruses.

211 rnal region (MPER), using a panel of 125 Env-pseudotyped viruses.

212 for neutralizing activity using 36 HIV-1 Env-pseudotyped viruses.

213 idually by analyzing infectivity assays with pseudotyped viruses.

214 Virions pseudotyped with 23 of the poorly transducing GPs were c

215 We generated here high-titer LVs pseudotyped with a baboon retroviral envelope glycoprote

216 eover, Ad-5/3-kappaBF512HRE, a viral variant pseudotyped with a chimeric 5/3 fiber, exerted a strong

217 Virions, pseudotyped with a class II, SFV E1 or VEEV E, or a clas

218 intravenous injection of a lentiviral vector pseudotyped with a modified chimeric Sindbis virus envel

219 d improved photoreceptor transduction by Ad5 pseudotyped with Ad35 (Ad5/F35) or Ad37 (Ad5/F37) fiber

220 ic stem cells (HSCs) with retroviral vectors pseudotyped with amphotropic envelopes.

221 A recombinant AAV2 vector pseudotyped with an HBoV1 capsid has been developed to e

222 However, the infectivity of HIV-1 pseudotyped with an MLV Env with the cytoplasmic tail fr

223 V containing a luciferase indicator gene and pseudotyped with an R5 envelope.

224 ave also examined infection with two viruses pseudotyped with CCR5- or CXCR4-tropic HIV-1 Env and hav

225 protein (GFP)-expressing proviral construct pseudotyped with CCR5-tropic or CXCR4-tropic envelope to

226 active Cameroonian sera did neutralize virus pseudotyped with chimeric Envs containing the 92UG037.8

227 pendent, as macrophage infections by virions pseudotyped with CXCR4 (X4)-tropic HIV-1 or vesicular st

228 compare the transduction efficiency of IDLVs pseudotyped with different envelopes (vesicular stomatit

229 neutralization of vesicular stomatitis virus pseudotyped with Ebola virus GP.

230 r envelope proteins replaced with EBOV GP or pseudotyped with EBOV GP.

231 ole of HIV-1 entry pathways by using viruses pseudotyped with either CCR5-tropic HIV-1 Env or vesicul

232 ebolavirus, as well as entry of retroviruses pseudotyped with either Lake Victoria marburgvirus or Za

233 These vectors were pseudotyped with either the vesicular stomatitis virus G

234 Viruses pseudotyped with env clones representative of each mater

235 Viruses pseudotyped with Env from JR-FL and BR025 were resistant

236 ces in neutralization sensitivities of HIV-1 pseudotyped with Env proteins derived from two prototypi

237 d had potent neutralizing activity for virus pseudotyped with envelope proteins (Env) from SF162, a n

238 to 10-fold higher than for previous vectors pseudotyped with envelope proteins from other alphavirus

239 Murine oncoretroviruses and lentiviruses pseudotyped with envelope proteins of alphaviruses have

240 e increased by the use of retroviral vectors pseudotyped with envelopes that recognize more abundant

241 ficant neutralizing activity against viruses pseudotyped with Envs from typically resistant clade B (

242 Hepatitis D virus (HDV) particles pseudotyped with HBV and WMHBV envelopes (HBV-HDV and WM

243 1b, as well as neutralization of lentivirus pseudotyped with HCV 1a and 1b envelope glycoproteins.

244 from these antibodies, retrovirus particles pseudotyped with HCV glycoproteins (HCVpp) isolated from

245 neutralized a panel of retroviral particles pseudotyped with HCV glycoproteins from six genotypes an

246 and, as negative controls, env-minus viruses pseudotyped with HIV-1, vesicular stomatitis virus, or m

247 ted vesicular stomatitis virus (VSV) virions pseudotyped with HSV-1 essential entry glycoproteins gB,

248 Recombinant vesicular stomatitis virus pseudotyped with LFV glycoprotein (GP) adopted the recep

249 Retroviruses pseudotyped with MACV and JUNV but not GTOV glycoprotein

250 ected cells, inhibited entry of retroviruses pseudotyped with Marburg virus GP(1,2), as well as Marbu

251 The infectivity of HIV-1 pseudotyped with murine leukemia virus (MLV) Env was not

252 ion of human T cells by HIV reporter viruses pseudotyped with R5-tropic gp120 envelope proteins but h

253 otyped lentiviral vector but not with vector pseudotyped with RD114.

254 ACE2, the entry of SARS-CoV or a lentivirus pseudotyped with SARS-CoV S protein in differentiated ep

255 oth expressing green fluorescent protein and pseudotyped with SARS-CoV S protein or S-protein variant

256 of compounds for blocking of entry of HIV-1 pseudotyped with SARS-CoV surface glycoprotein S (SARS-S

257 to selectively bind to retroviral particles pseudotyped with SARS-S.

258 infusion of 1x10(12) vg/kg scAAV-LP1-hFIXco pseudotyped with serotype 8 capsid, in 3 macaques, resul

259 By contrast, viruses pseudotyped with subtype A and C Env proteins were able

260 Virus pseudotyped with subtype B Env showed robust entry via C

261 Hepatitis D virus particles pseudotyped with surface proteins of U. bilobatum HBV, b

262 -type Ad37 and gene delivery by an Ad vector pseudotyped with the Ad37 fiber, but not by a vector bea

263 activity, with mammalian retroviral vectors pseudotyped with the ASLV-A envelope glycoprotein (EnvA)

264 ere resistant to infection with a MLV vector pseudotyped with the ASLV-A envelope protein but were fu

265 Lentiviruses (LVs) pseudotyped with the chimeric GPs were evaluated in term

266 iencies in human MSCs of HIV-1-based vectors pseudotyped with the chimeric RD114 GP were similar to t

267 nctional env genes and characterized viruses pseudotyped with the Env proteins in a single-round drug

268 murine oncoretroviral and lentiviral vectors pseudotyped with the envelope proteins of Venezuelan equ

269 tor signaling, enhanced the entry of viruses pseudotyped with the glycoprotein of lymphocytic choriom

270 cycle simian immunodeficiency viruses (SIVs) pseudotyped with the glycoprotein of vesicular stomatiti

271 tructed and characterized single-cycle SIVs, pseudotyped with the glycoprotein of vesicular stomatiti

272 s markedly enhanced the infection of viruses pseudotyped with the GP of Machupo, Guanarito and Junin

273 t not infection by HCoV-NL63 or a retrovirus pseudotyped with the HCoV-NL63 S protein.

274 e; therefore, recombinant HDV particles were pseudotyped with the hepadnaviral envelopes containing c

275 ed infection by SARS-CoV and by a retrovirus pseudotyped with the SARS-CoV spike (S) protein but not

276 f BDCA-1+ DCs are infected when the virus is pseudotyped with the vesicular stomatitis envelope VSV-G

277 imaged fusion of single retroviral particles pseudotyped with the vesicular stomatitis virus (VSV) G

278 ed with a murine leukemia virus (MLV) vector pseudotyped with the vesicular stomatitis virus glycopro

279 s effect was not observed with HIV-1 virions pseudotyped with the vesicular stomatitis virus glycopro

280 ansduction efficiencies with virus particles pseudotyped with the VSV-G GP were found to be high, RD1

281 similar to those obtained with HIV-1 vectors pseudotyped with the VSV-G GP.

282 nded the HDV system to include HDV particles pseudotyped with the WMHBV envelope.

283 Reporter virus particles pseudotyped with this E protein infected cells using eit

284 Whole-virus particles pseudotyped with TR1.3 Env similarly displayed a markedl

285 y of lentiviral and gamma-retroviral vectors pseudotyped with various envelope glycoproteins.

286 ection were investigated using MLV particles pseudotyped with vesicular stomatitis virus (VSV) G glyc

287 HD5 and HD6 promoted HIV reporter viruses pseudotyped with vesicular stomatitis virus and murine l

288 HIV-1 pseudotyped with vesicular stomatitis virus envelope-inf

289 replication of human immunodeficiency virus pseudotyped with vesicular stomatitis virus G protein an

290 upon infection of mouse DCs with HIV-1 cores pseudotyped with vesicular stomatitis virus G protein.

291 function increased the infectivity of HIV-1 pseudotyped with vesicular stomatitis virus G protein.

292 the Moloney murine leukemia retrovirus (MLV) pseudotyped with vesicular stomatitis virus glycoprotein

293 e for HSPC transduction enhancement with LVs pseudotyped with vesicular stomatitis virus glycoprotein

294 lycoprotein S (SARS-S) but not that of HIV-1 pseudotyped with vesicular stomatitis virus surface glyc

295 VBIM virus particles are pseudotyped with VSV G protein, allowing efficient infec

296 T cells with lentiviral particles that were pseudotyped with VSV-G or CXCR4-tropic HIV Env and assay

297 ted by a human immunodeficiency virus vector pseudotyped with VSV-G.

298 an immunodeficiency chimeric virus particles pseudotyped with XMRV envelope protein were used to demo

299 of a green fluorescent protein (GFP) vector pseudotyped with XMRV produced GFP(+) CD4(+) T cells and

300 , the polytropic MuLV genome was extensively pseudotyped within ecotropic virions; polytropic virus r